What is Wedbush’s Estimate for BDTX Q1 Earnings?

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) – Equities researchers at Wedbush issued their Q1 2026 EPS estimates for Black Diamond Therapeutics in a research note issued to investors on Friday, March 7th. Wedbush analyst R. Driscoll expects that the company will earn ($0.22) per share for the quarter. Wedbush has a “Outperform” rating and a $11.00 price objective on the stock. The consensus estimate for Black Diamond Therapeutics’ current full-year earnings is ($1.30) per share. Wedbush also issued estimates for Black Diamond Therapeutics’ Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.23) EPS and Q4 2026 earnings at ($0.24) EPS.

Separately, Stifel Nicolaus dropped their price objective on Black Diamond Therapeutics from $16.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, March 7th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Black Diamond Therapeutics has an average rating of “Buy” and a consensus price target of $14.40.

Black Diamond Therapeutics Price Performance

BDTX opened at $1.69 on Monday. The firm has a fifty day moving average price of $2.22 and a 200 day moving average price of $3.10. Black Diamond Therapeutics has a 1 year low of $1.59 and a 1 year high of $7.66. The stock has a market cap of $95.63 million, a P/E ratio of -1.27 and a beta of 2.52.

Black Diamond Therapeutics (NASDAQ:BDTX) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.03.

Institutional Investors Weigh In On Black Diamond Therapeutics

A number of hedge funds have recently modified their holdings of the business. D. E. Shaw & Co. Inc. purchased a new position in Black Diamond Therapeutics in the 4th quarter worth approximately $37,000. Intech Investment Management LLC lifted its position in Black Diamond Therapeutics by 49.1% during the fourth quarter. Intech Investment Management LLC now owns 19,247 shares of the company’s stock worth $41,000 after buying an additional 6,340 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Black Diamond Therapeutics by 429.6% during the fourth quarter. JPMorgan Chase & Co. now owns 18,929 shares of the company’s stock worth $41,000 after buying an additional 15,355 shares in the last quarter. SG Americas Securities LLC acquired a new position in Black Diamond Therapeutics during the fourth quarter worth $42,000. Finally, Wells Fargo & Company MN grew its holdings in Black Diamond Therapeutics by 41.8% in the 4th quarter. Wells Fargo & Company MN now owns 20,119 shares of the company’s stock valued at $43,000 after buying an additional 5,932 shares in the last quarter. 95.47% of the stock is currently owned by institutional investors and hedge funds.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.